News & Events
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.
READ MORENew Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology
A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE) on September 8, 2020.
READ MORECrinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) appointments Camille L. Bedrosian, M.
READ MORECrinetics Pharmaceuticals to Participate in September Investor Conferences
Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.
READ MOREFDA Grants Crinetics Pharmaceuticals (CRNX) Orphan Drug Designation - Paltusotine for the Treatment of Acromegaly
The orphan drug designation by the FDA for paltusotine to treat acromegaly validates the encouraging clinical data we have seen so far in the Phase 2 ACROBAT Edge clinical trial, and underscores the need for a once daily oral treatment option for patients suffering from this rare disease,” said Michael Monahan, Senior Director of Regulatory Affairs at Crinetics. "
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
